Merck secures a positive EU CHMP opinion for belzutifan plus lenvatinib in advanced clear-cell renal cell carcinoma, supported by Phase 3 LITESPARK-011 results.
Written By: Saniya Katakdhond, PharmD
Reviewed By: Pharmacally Editorial Team
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of belzutifan (WELIREG®) in combination with lenvatinib for adults with advanced renal cell carcinoma (RCC) containing a clear-cell component whose disease has progressed following PD-1 or PD-L1 inhibitor therapy.
The recommendation is supported by results from the Phase 3 LITESPARK-011 trial, which demonstrated a statistically significant progression-free survival (PFS) advantage over cabozantinib, though the final overall survival (OS) analysis did not reach statistical significance. If authorized by the European Commission which is expected to issue a final decision for the EU, Iceland, Liechtenstein, and Norway within two months—the regimen would introduce the first pairing of a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor and a multi-targeted VEGFR tyrosine kinase inhibitor (TKI) in this setting.
Phase 3 LITESPARK-011: Clinical Evidence
LITESPARK-011 (NCT04586231) is a randomized, open-label Phase 3 trial that enrolled 747 patients with advanced clear-cell RCC (ccRCC) who experienced disease progression during or after PD-1/PD-L1 inhibitor treatment, or within six months of completing adjuvant PD-1 therapy. Patients were randomized 1:1 to receive either belzutifan (120 mg once daily) plus lenvatinib (20 mg once daily) or cabozantinib (60 mg once daily). Dual primary endpoints were PFS assessed by blinded independent central review and OS.
- Progression-Free Survival (PFS): Belzutifan plus lenvatinib reduced the risk of disease progression or death by 26% compared with cabozantinib (HR 0.74; 95% CI, 0.62–0.88), extending median PFS to approximately 14.8 months versus 10.8 months.
- Overall Survival (OS): The final OS analysis did not meet statistical significance. Median OS was 33.7 months with the combination versus 28.6 months with cabozantinib (HR 0.85; 95% CI, 0.70–1.03); the one-sided p-value of 0.04689 did not cross the prespecified significance boundary of 0.0223, meaning a survival benefit was not established.
- Response Outcomes: The combination achieved a higher objective response rate (53.1% vs. 40.2%) and nearly doubled the median duration of response (22.0 months vs. 11.9 months) compared with cabozantinib, indicating greater antitumour activity and response durability.
Safety and Treatment Considerations
Serious adverse reactions occurred in 54% of patients treated with belzutifan plus lenvatinib, most notably hypoxia (6%), pneumonia (5%), hyponatraemia (3.2%), acute kidney injury (3%), haemorrhage (2.7%), anaemia (2.7%), cardiac failure (2.4%), and diarrhoea (2.4%). Fatal adverse reactions occurred in 5% of patients.
Toxicity management required frequent dose modifications:
- Dose interruptions: 69% of patients
- Dose reductions: 35% of patients
- Permanent discontinuation of belzutifan: 17% of patients
Because anaemia, fatigue, and hypertension were among the most common adverse events or laboratory abnormalities, patients receiving this combination require regular monitoring of haemoglobin levels, oxygen saturation, blood pressure, and renal and cardiac function.
Clinical and Regulatory Outlook
LITESPARK-011 demonstrates that dual HIF-2α and VEGFR-TKI inhibition improves disease control and response durability over standard cabozantinib monotherapy in post-immunotherapy advanced ccRCC. However, the lack of a statistically significant OS advantage and the notable rate of serious adverse events and dose interruptions remain key considerations. Pending final European Commission authorization, clinicians will need to weigh this regimen’s superior PFS and response profile against its toxicity burden when sequencing therapies after PD-1/PD-L1 failure.
Reference
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination with Lenvatinib for Adults with Advanced Renal Cell Carcinoma with a Clear Cell Component (ccRCC) Following Treatment with an Anti-PD-1/PD-L1 Therapy, Merck, 13 November 2026
A Study of Belzutifan (MK-6482) in Combination with Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011), ClinicalTrials.gov ID NCT04586231
About the Writer
Saniya Sanjay Katakdhond (Linkedin) is a Doctor of Pharmacy professional with hands-on experience in patient case review, clinical documentation, medical record analysis, and patient care.
Her hospital experience has strengthened her understanding of clinical conditions, treatment approaches, and multidisciplinary healthcare practices.
With ICH-GCP certification and a research-oriented approach, she brings clinical insight and attention to detail to healthcare content development.
As a healthcare writer, Saniya focuses on translating clinical knowledge and patient-care experience into clear, accurate, and evidence-informed medical content.